Filomena Adega is Assistant Professor in the Department of Genetics at the University of Trás-os-Montes and Alto Douro, the Coordinator of the Service Provider Unit, Genetics4U, at UTAD and an integrated member of the Institute of Biosystems and Integrative Sciences, BioISI-Polo UTAD. Has participated or is participating in scientific research projects in the areas of Comparative Genomics, Chromosome Architectures, Genome adaptation, evolution and disease impacted by the ‘Satellitome’ and the ‘Mobilome’, scientific areas in which she has been publishing since 2002. She actively collaborates with various research groups around the world in her areas of expertise. To date, has supervised or co-supervised eight PhD, 21 MSc and 39 undergraduate students, contributing to the increase of highly specialized human resources. She is responsible for the laser microdissection station, the in vitro animal cell culture and the confocal microscopy unit facilities of UTAD’s CytoGenomics Lab.

Carmen Jerónimo, is Director of the IPO Research Center (since 2021), Scientific Coordinator of the Porto IPO Biobank (since 2016) and Coordinator of the Epigenetics and Cancer Biology Group (since 2008).
She obtained a Degree in Biology (1994), Master’s in Oncology (1998), PhD in Biomedical Sciences (2001) and Aggregation in Pathology and Molecular Genetics (2011) at Porto University.

She developed his doctoral project within the scope of the GABBA Doctoral Program at the Johns Hopkins University School of Medicine (JHU), in Baltimore, MD, USA, working on genetic and epigenetic alterations in prostate cancer. She was a post-doctoral fellow in collaboration with JHU (2001-2004) and a guest researcher at IPO Porto (2004-2008).

Her research at the IPO Porto Research Center focuses on characterizing the epigenome of tumor cells, as well as identifying the functional changes involved in the dysregulation of cellular epigenetic homeostasis. In the context of Personalized Medicine, she works on the development of new epigenetic cancer biomarkers based on liquid biopsies, as well as drug discovery based on the modulation of epigenetic aberrations. Due to the relevance that Immuno-oncology has demonstrated in recent years, it also investigates the modulation of the epigenetic expression of biomolecules involved in immune regulation, aiming to improve immunotherapeutic strategies by combining with epi-drugs. More recently, she has begun to address the contribution of dysregulated non-coding RNAs and their interaction with other epigenetic mechanisms in malignant transformation.
She is currently the Clinical Epigenetics Section Editor and Associate Editor of the International Journal of Molecular Sciences and Epigenomes. She regularly acts as an ad hoc reviewer of several scientific journals and grants/research projects from national agencies (FCT Investigator Call 2013 and 2015) and international agencies (2003-Health Research Board- HRB-IR; 2006-Associazione Italiana per la Ricerca sul Cancro; 2015-FWF Austrian Science Fund;
She has authored or co-authored more than 250 international scientific publications, including 11 book chapters and 54 review articles (H-index 55; Web of Science 12/2023), including first quartile (Q1) journals, including: Clin Cancer Res , Cancers, Cancer Letters, Cell Death Dis, Br J Cancer, Eur J Cancer, J Cell Mol Med, J Hematol Oncol, JNCI, Mol Cancer, Mol Oncol, Nat Commun, Oncogene and PNAS.

PhD in Biology with specialization in Genetics and Master in Human Molecular Biology from the Faculty of Sciences of the University of Lisbon, degree in Biomedical Laboratorial Sciences. Adjunct Professor at School of Health Technology School of Lisbon – Polytechnic Institute of Lisbon. She is part of several international and national projects, author of 1 book, 8 book chapters, around 40 scientific articles in journals with an impact factor, 50 oral communications and 100 poster communications. Her research interests are in human biomonitoring, genetic toxicology, environmental and occupational exposure, among others subjects. She was a member of scientific and organizing committees for several national and international events, as well as moderating tables at scientific events.

HL holds a Ph.D in Public Health – Environmental and Occupational Health (ENSP, Nova University of Lisbon, Portugal) and is graduated in Biochemistry (Faculty of Sciences, Lisbon University). She works as research scientist in the field of genetic toxicology, since 1997, involved in studies in human biomonitoring and nanotoxicology, with participation in European projects such as Nanogenotox, Nanoreg, HBM4EU, and the ongoing European Partnership for the Assessment of Risks from Chemicals (PARC). She is a member the cross-cutting Working Groups on Genotoxicity of the European Food Safety Authority (EFSA), Nanotechnologies and NAMs. As of 2023, is a genotoxicity expert for Scientific Committee for Consumer Safety (SCCS).

Ana Teresa Reis is a researcher at the Nanomaterials: Safety and Health Lab, part of the Integrative and Translational Research in Population Health (ITR) Associated Laboratory / Instituto de Saúde Pública da Universidade do Porto. Her research focuses on understanding the biological effects of human exposure to mixtures of legacy and emerging environmental contaminants, using both in vitro and in vivo models, and in the development of novel approaches to predict the toxicity of these contaminants. In this area, she coordinates projects NanoLegaTox (POCI-01-0145-FEDER-029651) and MixIng-Tox (2022.03491.PTDC).